Motif Bio is forging ahead with plans to list its stock on Nasdaq to raise the cash it needs to wrap up a Phase III trial of its antibiotic, iclaprim.

French NASH and fibrosis disease biotech Inventiva is looking to build on its Big Pharma interest by filing for an IPO on the Euronext.

He’s only been Arena’s president and CEO for two months, but biotech vet Amit Munshi is wasting no time getting to know his new staff as the company announces…

Tesaro posted stellar Phase III results yesterday for its PARP inhibitor in ovarian cancer. But following on its good vibes have been other PARP R&D…

It was a shock result for the U.K. this morning as the public decided by a narrow margin of 52-48 to leave the European Union, in what will have a profound…

Eleven Biotherapeutics, which has valiantly (or stubbornly) carried on over the past 12 months despite a slew of major trial failures, is now, finally, nearing…

On June 17, Neil Woodford upped his stake in Circassia. The next business day, Circassia posted Phase III trial data that caused its stock price to crash.

Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-…